120 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
41 Recruiting Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design: Time Perspective: Retrospective
Number Enrolled: 1000
Gender: Both
Age Groups: Child / Adult / Senior
NCT Number: NCT00899275
42 Recruiting Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Number Enrolled: 1000
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT00897325
43 Recruiting Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Conditions: Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen Citrate;   Drug: Topotecan Hydrochloride;   Drug: Trametinib
Study Type: Interventional
Phases: Phase 2 / Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Crossover Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 250
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT02101788
44 Unknown  Second Curettage in Treating Patients With Persistent Non-Metastatic Gestational Trophoblastic Tumor
Condition: Gestational Trophoblastic Tumor
Interventions: Other: laboratory biomarker analysis;   Procedure: conventional surgery
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 66
Gender: Female
Age Groups: Child / Adult / Senior
NCT Number: NCT00521118
45 Recruiting Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 1520
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT00936390
46 Recruiting Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Brenner Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage III Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Behavioral: Behavioral Dietary Intervention;   Behavioral: Compliance Monitoring;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Prevention;   Masking: Open Label
Number Enrolled: 1070
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT00719303
47 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive Side Effects of Cancer Therapy;   Psychological Impact of Cancer;   Radiation Toxicity;   Sexual Dysfunction and Infertility;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 780
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT01414608
48 Recruiting Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma or Low Grade Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 360
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT00887146
49 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 1636
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT01872975
50 Recruiting Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Conditions: Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Recurrent Brain Neoplasm
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Biological: Bevacizumab;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Proton Beam Radiation Therapy
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 178
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02671981
51 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 4895
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT01406756
52 Recruiting Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia;   Leukemia Cutis;   Myeloid Sarcoma;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
Interventions: Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 1250
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT01371981
53 Recruiting Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Conditions: PRETEXT Stage 1 Hepatoblastoma;   PRETEXT Stage 2 Hepatoblastoma;   PRETEXT Stage 3 Hepatoblastoma;   PRETEXT Stage 4 Hepatoblastoma
Interventions: Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 253
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT00980460
54 Recruiting A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Condition: Early Stage HER2+ Breast Cancer
Interventions: Drug: Neratinib;   Drug: Loperamide
Study Type: Interventional
Phase: Phase 2
Funder Type: Industry
Study Design: Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 120
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02400476
55 Recruiting Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castrate Resistant Prostate Cancer
Interventions: Biological: Dendritic Cells DCVAC;   Biological: Placebo;   Drug: Docetaxel;   Drug: Taxotere
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject, Caregiver, Investigator)
Number Enrolled: 1170
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT02111577
56 Recruiting Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Conditions: Adult Fibrosarcoma;   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
Study Type: Interventional
Phases: Phase 2 / Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 340
Gender: Both
Age Groups: Child / Adult / Senior
NCT Number: NCT02180867
57 Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 100
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01164228
58 Unknown  Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: pentostatin
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 110
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT00074282
59 Recruiting Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Conditions: Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 140
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT02306161
60 Recruiting Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Conditions: Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 1400
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT02112916

First Page    Show previous page of results Previous Page (21-40) Studies Shown (41-60) Next Page (61-80) Show next page of results    Last Page
Indicates status has not been verified in more than two years